305 related articles for article (PubMed ID: 34201529)
1. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.
Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P
Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878
[TBL] [Abstract][Full Text] [Related]
3. Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice.
Berzero G; Picca A; Psimaras D
Curr Opin Oncol; 2020 Nov; 32(6):603-612. PubMed ID: 32852312
[TBL] [Abstract][Full Text] [Related]
4. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.
Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P
Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992
[TBL] [Abstract][Full Text] [Related]
8. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Perrinjaquet C; Desbaillets N; Hottinger AF
Curr Opin Neurol; 2019 Jun; 32(3):500-510. PubMed ID: 30893101
[TBL] [Abstract][Full Text] [Related]
9. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
10. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
Lipe DN; Shafer S
Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
[TBL] [Abstract][Full Text] [Related]
11. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733
[TBL] [Abstract][Full Text] [Related]
12. Understanding and treating the inflammatory adverse events of cancer immunotherapy.
Dougan M; Luoma AM; Dougan SK; Wucherpfennig KW
Cell; 2021 Mar; 184(6):1575-1588. PubMed ID: 33675691
[TBL] [Abstract][Full Text] [Related]
13. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
14. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
Fishman JA; Hogan JI; Maus MV
Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
[TBL] [Abstract][Full Text] [Related]
17. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
Okiyama N; Tanaka R
Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
20. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
